Groundbreaking stem cell treatment is offering a dad-of three a life changing chance.
Five years after unsuccessful treatment in Poland for his multiple sclerosis, the 33-year-old, is travelling to London for the most up-to-date stem cell therapy.
Barry McArthur is currently confined to a wheelchair, is dependent on wife Katy and cannot play with his three young sons.
When he made the journey to Poland he was convinced the £10,000 he’d scraped together to fund a special vein irrigation treatment would pay off. But the Katowice clinic experiment failed, offering little more than a false dawn to the many hopeful Scots who had travelled to Eastern Europe, such as radio legend Tiger Tim Stevens.
But the Katowice clinic experiment failed, offering little more than a false dawn to the many hopeful Scots who had travelled to Eastern Europe, such as radio legend Tiger Tim Stevens.
The lifeline which could enable him to live out a life he’s dreamed of since he was diagnosed with the neurodegenerative disease in his early twenties.
That includes returning to work as a quantity surveyor and kicking a ball in the park with his three little boys.
He said: “I’ve been researching stem cell treatments for MS and this treatment is getting great results.
“And next month I’m set to go down to the Charing Cross hospital and have my first examination, to make sure my body can cope.”
MS is an autoimmune disease, where the body’s immune system attacks its own nerve cells.
This affects nerves in the brain and spinal cord, causing problems with muscle movement, balance and vision.
The new stem cell treatment involves using high doses of chemotherapy to “knock out” the existing faulty cells of the immune system, before rebuilding it using clean stem cells taken from the patient’s own blood.
The process has been described as ‘like giving the immune system the chance to reboot.’ The stem cell treatments however, won’t work (at this stage at least) for the sufferers of the illness who have had the disease for more than 10 years.
And not everyone will be able to tolerate the aggressive chemotherapy used.
To read the full article click here.
BSc (Hons) Microbiology
Biovault Family CEO, Kate Sneddon, joined Biovault in July 2009 and became Chief Executive Officer in 2016. As health industry professional her experience includes working as a microbiologist and leader at GSK for over 10 years. Her expertise in cord blood banking has been recognised in her awards, features in Parliamentary Review and Parents Guide to Cord Blood, as well as contributions to research with UCL and others.